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Abstract 
More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept of 
somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors (NET) is 
seeing rapidly increasing use. To maximize the full potential of its theranostic promise, efforts in 
recent years have expanded recommendations in current guidelines and included the evaluation of 
novel theranostic radiotracers for imaging and treatment of NET. Moreover, the introduction of 
standardized reporting framework systems may harmonize PET reading, address pitfalls in 
interpreting SSTR-PET/CT scans and guide the treating physician in selecting PRRT candidates. 
Notably, the concept of PRRT has also been applied beyond oncology, e.g. for treatment of 
inflammatory conditions like sarcoidosis. Future perspectives may include the efficacy evaluation of 
PRRT compared to other common treatment options for NET, novel strategies for closer 
monitoring of potential side effects, the introduction of novel radiotracers with beneficial 
pharmacodynamic and kinetic properties or the use of supervised machine learning approaches for 
outcome prediction. This article reviews how the SSTR-directed theranostic concept is currently 
applied and also reflects on recent developments that hold promise for the future of theranostics in 
this context. 
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Introduction 
More than 25 years after the first peptide 
receptor radionuclide therapy (PRRT) with 
[111In]-pentetreotide at the Department of Nuclear 
Medicine at the Erasmus Medical Center, Rotterdam, 
the concept of somatostatin receptor (SSTR)-targeted 
imaging and therapy for neuroendocrine tumors 
(NET) is seeing rapidly expanding use, in particular 
as cumulative experience with NET is now readily 
transferred to other diseases [1]. The most notable 
examples of this are prostate-specific membrane 
antigen (PSMA) radioligand therapy for the treatment 









endoradiotherapy for chemokine receptor-expressing 
malignancies [3].  
The theranostic principle is based on the concept 
of diagnostic molecular imaging, followed by an 
individually tailored treatment decision. In the field of 
NET, the theranostic principle relates to the pairing of 
[111In]-/[68Ga]-labeled diagnostic single photon 
emission computed tomography (SPECT) or positron 
emission tomography (PET) imaging agents and 
[90Y]-/[177Lu]-labeled therapy compounds [4]. In this 
regard, the most established radiotracers are 
[68Ga]-labeled 1,4,7,10-tetraazacyclododecane-N,N', 
N'',N'''-tetraacetic acid-d-Phe(1)-Tyr(3)-octreotide/ 
-octreotate ([68Ga]-DOTATOC/-TATE). Sufficient 
uptake on PET with those imaging probes guides the 
referring nuclear medicine physician towards 
[177Lu]-DOTATATE/-TOC therapy [5].  
In recent years, the theranostic concept in NET 
has continuously evolved to meet the challenging 
needs of NET patients and to exploit its full 
theranostic potential that is maximum treatment effect 
with minimal risk of potential harm [6]. Such efforts 
include, but are not limited to, harmonization of 
SSTR-targeted PET/CT interpretation, expansion of 
the theranostics concept to applications beyond 
oncology, and the introduction of novel radionuclides 
for the treatment of NET [7-20]. In the present 
manuscript, the theranostic principle will be briefly 
introduced, the potential paradigm shift in the use of 
current “state-of-the-art” theranostic radionuclides 
will be summarized, and novel applications for PRRT 
will be reviewed. In addition, recently introduced 
standardized framework systems for the 
interpretation of SSTR-targeted PET/CT and their 
impact on subsequent decision-making will be 
discussed. Moreover, emerging novel radiotracers for 
theranostics in NET which may become a therapeutic 
option after treatment failure with conventional PRRT 
will be presented. Finally, future perspectives in the 
field of molecular imaging and treatment for NET will 
be outlined. 
The Theranostics Principle in NET 
Theranostic Concept. As an underlying biological 
rationale for the theranostic principle in NET, 
membrane-bound receptors on the NET cell surface 
offer the possibility to be targeted by molecular 
diagnostic and therapeutic probes. Those receptors 
include SSTR1, SSTR2, SSTR3, SSTR4 and SSTR5, and 
the available radionuclides differ in their binding 
affinities towards such receptors with most agents 
having the highest affinity for SSTR2 and SSTR5 [4, 21, 
22]. In brief, following confirmation of high SSTR 
expression with diagnostic SSTR-targeted 
radiotracers, therapeutic radiolabeled compounds 
(“hot“ somatostatin analogs) can be administered and 
bind to the SSTR on the tumor cell surface. After 
internalization into the NET cell, ß-irradiation from 
the compound provokes DNA strand breaks, which 
ultimately lead to cell death. Of note, current 
“state-of-the-art” therapeutic radiopharmaceuticals 
(e.g. [177Lu]-DOTATATE/-TOC) use an agonist- 
induced mechanism to enter the cell. Thereafter, 
endosome-mediated recycling leads to the 
replacement of SSTR on the tumor cell surface within 
24 hours. Thus, the theranostic concept in NET 
resembles a Trojan horse mechanism, as the SSTR 
density on the tumor cell surface opens the door for 
high affinity binding of the radiolabeled compound 
with subsequent internalization into the NET cell [4, 
23].  
The NETTER-1 Trial. As the first randomized, 
controlled trial demonstrating the efficacy and safety 
of [177Lu]-DOTATATE PRRT, the NETTER-1 trial 
marked an important milestone for the treatment of 
NET: In patients with well-differentiated, metastatic 
midgut NET that failed 1st-line therapy with 
unlabeled somatostatin analogs, a PRRT group 
([177Lu]-DOTATATE plus “cold” octreotide long 
acting release (LAR) 30mg) was compared with a 
control group receiving only high-dose octreotide 
LAR (60mg). PFS had not yet been reached in the 
PRRT group at the time of publication of NETTER-1, 
but was 8.4 months in the control group. The 
estimated rate of PFS at month 20 was 65.2% in the 
[177Lu] group and 10.8% in the cold octreotide LAR 
group. A recently published update on PFS further 
corroborated those initial findings [24]. Moreover, at 
date of censoring, 14 deaths had occurred in the 
[177Lu]-DOTATATE arm (vs. 26 in the control group), 
i.e. the estimated risk of death was 60% lower for 
patients undergoing PRRT. Common Terminonology 
Criteria for Adverse Events (CTCAE) grade 3 or 4 
toxicities were observed for hematotoxicity 
(myelosuppression in 9%), while no severe 
nephrotoxicity (grade 3 or 4) was recorded [25]. In 
addition, time to health-related Quality of Life (QoL) 
deterioration showed that the time span until 
worsening of global health status, disease-related 
mental stress, or symptoms (e.g. diarrhea) was 
significantly longer in the PRRT arm as compared to 
the control group [26]. Furthermore, PFS of the [177Lu] 
group was not impacted by an initially impaired renal 
function [27]. Taken together, the NETTER-1 trial 
provided evidence that PRRT, in combination with 
low-dose octreotide LAR, not only markedly 
improved PFS, response rates, and survival 
probability, but also inferred a significant QoL benefit 
to patients [25, 26].  
 





Expanding Current Recommendations for 
“State-of-the-Art” Theranostic Agents  
In 2013, spearheaded by Bodei et al., the “Joint 
International Atomic Energy Agency, European 
Association of Nuclear Medicine and Society of 
Nuclear Medicine and Molecular Imaging Practical 
Guidance” provided advice on how to implement 
PRRT for NET in clinical practice [5]. This document 
included indications, contraindications, and patient 
preparation advice. In this regard, several paradigms 
towards an ideal application of PRRT were 
established [5], which later were also adapted by 
other national and international guidelines [28, 29]. 
However, given the high number of patients treated at 
multiple sites with long and continuously increasing 
follow-up, recent studies have added to the 
complexity of PRRT in NET and expanded upon those 
previously established principles.  
For instance, current international guidelines 
recommend to restrict PRRT to WHO Grade 1/2 (Ki67 
≤ 20%) NET patients and thus, the majority of the 
performed studies to date (including the NETTER-1 
trial) are limited to well-differentiated G1-2 diseases 
[5, 25, 28]. However, PRRT might be an option in a 
subgroup of G3 neuroendocrine neoplasms: The 
“NORDIC Neuroendocarcinoma (NEC)” study included 
305 patients from 12 Nordic hospitals with 
gastrointestinal G3 disease [30]. The vast majority of 
the patients had received platinum-based 
chemotherapy (252/305, 82.6%), while the remainder 
had been treated with best supportive care (53/305, 
17.4%). A Ki67 < 55% demonstrated less 
responsiveness to chemotherapy (based on 
radiological response assessment) [30]. Those findings 
have been compared to a pilot study cohort of G3 
NEN with a Ki67 > 55% vs. < 55% treated with PRRT 
(in combination with radiosensitizing chemotherapy). 
It could be demonstrated that the median OS for those 
subjects with a Ki67 below that threshold was 
considerably longer in the PRRT cohort (46 months vs. 
14 months in the NORDIC trial), while the opposite 
was documented in patients with a Ki67 > 55% (PRRT, 
7 months vs. NORDIC, 10 months) [30, 31]. Based on 
this preliminary data, PRRT might be a promising 
treatment option in progressive G3 NET. However, 
temozolomide alone or in combination with 
capecitabine and/or bevacizumab as 2nd-line 
treatment in patients with Ki67 < 60% have also 
demonstrated high response rates of up to > 70% in 
patients with progressive disease after 1st-line 
treatment [32, 33] and no head-to-head comparison 
has been performed so far.  
Nicolini and coworkers identified a Ki67 ≤ 35% 
as the optimal threshold to predict disease control 
under PRRT [34]. Altogether, given high 
SSTR-expression as treatment rationale/pre-requisite, 
PRRT (combined with a radiosensitizer) may be an 
alternative option in G3 NEN patients with Ki67 < 
55% (or more preferably in subjects with Ki67 ≤ 35%). 
Nonetheless, future prospective, randomized, 
controlled studies are warranted to corroborate these 
preliminary findings. 
Current guidelines suggest 3-5 cycles of 
[177Lu]-based PRRT [5, 28]. However, Yordanova et al. 
expanded upon that recommendation as they 
retrospectively evaluated a total of 15 patients who 
had received a median of 9 cycles (range, 8-13 cycles) 
with a median cumulative administered activity of 
63.8 GBq (range, 52-95.6 GBq). First and foremost, no 
life-threatening adverse events (CTCAE 4) occurred. 
No CTCAE 3/4 nephrotoxicity and only one 
reversible case of CTCAE 3 hematotoxicity were 
documented, further emphasizing the favorable 
safety profile of such repeated treatment cycles. Of 
note, compared to historical controls receiving a 
maximum of 4 cycles, a considerably higher survival 
benefit of 85.6 months (vs. 69.7 months in the group 
with less cycles) was demonstrated [35]. In a similar 
vein, McEwan and coworkers from Edmonton, 
Canada are currently performing a maintenance 
protocol, which includes up to 8 PRRT cycles with 3.7 
GBq (every 6 – 10 months) after an induction protocol 
of 4 cycles up to 5.55 GBq/cycle (every 2.5 – 3.5 
months). Notably, in their enrolled cohort of 138 
patients, the median PFS has not been reached at 59.3 
months [36].  
Novel Targets for PRRT: Beyond Current 
Applications 
Beyond current applications in 
gastroenteropancreatic (GEP)-NETs, other potential 
targets in oncology include meningioma, lung NET 
(including small cell lung cancer), and malignant 
pheochromocytoma/paraganglioma [5, 37-39]. For 
the latter tumor entity, favorable results have been 
recently demonstrated: In a proof-of-concept study 
including four patients suffering from hereditary 
paraganglioma in whom surgical resection was not 
feasible, up to 5 cycles of [177Lu]-DOTATATE led to 
partial response or stable disease in all subjects [40, 
41].  
In addition to the tumor cell surface, SSTR are 
also expressed by other cell types in non-oncologic 
conditions. For instance, Tarkin et al. and others were 
recently able to demonstrate SSTR2 gene 
overexpression exclusively in pro-inflammatory M1 
macrophages and subsequent specific binding of 
[68Ga]-DOTATATE in macrophage-rich inflammatory 
atherosclerotic carotid plaques [42, 43]. In a pilot 





study, Schatka et al. have already investigated a cohort 
of oncology patients who had been scheduled for 
PRRT and reported on the feasibility of characterizing 
SSTR2 expression in atherosclerotic plaques using 
[68Ga]-DOTATATE. In addition, a potential reduction 
effect in plaque activity using the therapeutic 
equivalent [177Lu]-DOTATATE was documented, thus 
suggesting avenues for anti-atherosclerotic 
interventions based on SSTR2-directed 
(endoradio-)therapies [11]. Beyond atherosclerosis, 
marking macrophage activity with radiolabeled 
SSTR2 ligands has been demonstrated in other 
inflammatory conditions, including myocardial 
infarction, myocarditis and sarcoidosis [44-46].  
In treatment-refractory sarcoidosis, Lapa and 
coworkers expanded the concept of [177Lu]-based 
SSTR-targeting endoradiotherapy. In a 
proof-of-concept study, two patients suffering from 
multi-organ involvement of sarcoidosis received a 
standard activity of 7.7 GBq in four treatment cycles, 
and, notably, both patients demonstrated a 
considerable benefit from PRRT (partial response, 
accompanied with a pronounced pain reduction in 
one patient and stable disease in the second patient, 
Figure 1). No adverse effects were recorded [10].  
Potential Novel Radiotracers after Failure 
of Conventional PRRT  
Notably, several new theranostic radiotracers for 
GEP-NET have been recently introduced and applied 
in a therapeutic setting. Thus, those agents may 
eventually be available to serve as an option after 
failure of conventional, agonist-based PRRT. 
[68Ga]-OPS202/[177Lu]-OPS201. The best- 
evaluated novel theranostic agent to date is the SSTR 
antagonist [68Ga]-NODAGA-JR11 (NODAGA = 
1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid 
and JR11 = Cpa-c(dCys-Aph(Hor)-dAph(Cbm)- 
Lys-Thr-Cys)-dTyr-NH2), also referred to as 
[68Ga]-OPS202 with its therapeutic partner 
[177Lu]-OPS201. In a prospective phase I study, the 
SSTR antagonist PET probe was evaluated in 12 GEP 
NET patients and safety, bio-distribution, dosimetry, 
and optimal imaging time point were evaluated. The 
highest radiation dose was observed in the urinary 
tract and the optimal time window for SSTR 
antagonist PET was between 1 – 2 hours post-injection 
[15]. A recently reported phase II study compared 
[68Ga]-OPS202 to its agonist counterpart 
[68Ga]-DOTATOC and the detection rate in 12 low- 
and intermediate GEP NET patients was higher with 
the novel SSTR-antagonist imaging agent. Notably, 
the authors also performed a second, subsequent 
[68Ga]-OPS202 scan with 50 μg peptide (first visit, 15 
μg peptide) and the lesion-based overall sensitivity 
was slightly higher with 50 μg of [68Ga]-OPS202 (94% 
for 50 μg vs. 88% for 15 μg of [68Ga]-OPS202 vs. 59% 
for 15 μg of [68Ga]-DOTATOC). Moreover, a high 
reproducibility between the first and the second SSTR 
antagonist PET was achieved [17]. The theranostic 
twin [177Lu]-OPS201 ([177Lu]-DOTA-JR11) was 
evaluated in two tumor-bearing murine models to 
allow for a comparison with the established 
equivalent [177Lu]-DOTATATE. Notably, up to 4.4 
times higher tumor doses per injected activity were 
detected with OPS201 (1.8 ± 0.7 Gy/MBq vs. 
[177Lu]-DOTATATE, 0.36 ± 0.07 Gy/MBq) [16, 47]. 
Biodistribution in pigs also demonstrated 
encouraging results, which forecasts radiation 
exposure in humans in an acceptable range [48]. A 
  
 
Figure 1. Display of [18F]-FDG PET/CT and somatostatin receptor-directed PET/CT with [68Ga]-DOTATOC before and 1 year after initiation of peptide receptor 
radionuclide therapy with [177Lu]-DOTATOC in a patient suffering from sarcoidosis. After a total of four cycles, stable disease (with a slight reduction in 
somatostatin receptor expression and increasing activity in the spleen) was recorded. Both PET projections are displayed with the same intensity. From Lapa et al., 
Theranostics, [10]. 





recently published abstract reported on 19 patients 
who underwent [68Ga]-OPS202 imaging and 
subsequent [177Lu]-OPS201 therapy (with 7/19 
receiving two cycles): 1 patient achieved a complete 
response, 32% partial response and 47% remained 
stable. G4 hematological toxicities occurred in half of 
the patients with two treatment cycles, which 
resolved to G2 or lower during follow-up [49]. A 
current, ongoing, recruiting trial (ClinicalTrials.gov 
Identifier: NCT02592707) may further evaluate the 
safety profile and efficacy of [177Lu]-OPS201 [50]. 
[177Lu]-DOTA-EB-TATE. Based on the common 
radionuclide [177Lu]-DOTATATE, first reports in 
multiple xenograft models reported on efficacy 
maximization by using an Evans blue modification of 
octreotate [13]. Given the markedly increased binding 
to circulating serum albumin, a slower clearance 
through the urinary tract and thus, an extended 
half-life in blood was observed. Consequently, an 
increase in tumor retention was demonstrated by 
using [86Y]/[90Y]-DOTA-EB-TATE in a variety of 
different cell lines and dedicated animal models with 
long term efficacy relative to DOTATATE in mice 
bearing SSTR2 xenografts [13]. The same research 
group subsequently investigated this radiotracer in a 
pilot cohort of NEN patients. In a head-to-head 
comparison with [177Lu]-DOTATATE, the total 
effective doses of both radiotracers were comparable 
([177Lu]-DOTA-EB-TATE, 0.205 mSv/MBq vs. 
[177Lu]-DOTATATE, 0.174 mSv/MBq). Notably, 
[177Lu]-DOTA-EB-TATE demonstrated a 7.9 fold 
increase of delivered tumor doses, which renders the 
concept of Evans Blue modification an attractive 
option [51]. In addition, 4 patients were treated with a 
single low-dose of [177Lu]-DOTA-EB-TATE (up to 0.72 
GBq) and compared to a control group undergoing 
conventional [177Lu]-DOTATATE treatment (maximal 
4.2 GBq). For molecular response evaluation, the delta 
(SUV) between baseline and follow-up 
[68Ga]-DOTATATE was assessed and no significant 
differences between the [177Lu]-DOTA-EB-TATE vs. 
the [177Lu]-DOTATATE groups were found. Notably, 
the EB-TATE group received approximately 1/6 of 
the total radiation exposure relative to the TATE 
group [14].  
[213Bi]-DOTATOC. Following animal studies 
using the alpha-emitters [213Bi]-DOTATOC (in a rat 
pancreatic tumor model) and 225Ac-DOTATOC (in 
nude mice), Kratochwil and coworkers performed 
targeted alpha therapy (TAT) with an intra-arterial 
infusion of [213Bi]-DOTATOC in 7 patients with 
advanced NET. All patients had undergone previous 
PRRT cycles with beta emitters (90Y or 177Lu) and 
presented with relapsed/refractory disease [52-54]. 
Notably, TAT showed considerable anti-tumor 
effects, and even overcame resistance against beta 
radiation. Moderate acute hematological side effects 
were observed, and chronic kidney impairment was 
in an acceptable range [54]. Recent improvement of 
labeling chemistry showed that labeling of 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(meth
ylenephosphonic acid) (DOTP) with [213Bi] instead of 
the currently used DOTA led to higher efficiency and 
in vitro stability [55]. Nonetheless, further studies 
enrolling larger patient cohorts are warranted to 
determine the role of TAT, in particular as an 
additional treatment line after resistance to common 
beta-emitters.  
[68Ga]-Pentixafor/[177Lu]-Pentixather. The C-X-C 
motif chemokine receptor CXCR4 is overexpressed on 
the NET cell surface. Kämmerer et al. reported on an 
inverse expression of SSTR2 and CXCR4 in G1 to G3 
NET in surgical GEP-NET samples with an 
upregulation of CXCR4 and a downregulation of 
SSTR occurring with increasing tumor grade [56]. 
These histological findings were further corroborated 
in vivo by using the novel CXCR4-targeting imaging 
probe [68Ga]-Pentixafor. In a triple-tracer approach 
([68Ga]-Pentixafor vs. [68Ga]-DOTATOC vs. 
2-deoxy-2-18F-fluoro-D-glucose ([18F]-FDG)), the 
majority of [68Ga]-Pentixafor-positive subjects showed 
a Ki67 of > 85% with concordant high glycolytic 
activity (assessed by [18F]-FDG PET) and markedly 
decreased (or even absent) SSTR-expression. Thus, 
endoradiotherapy with [177Lu]-Pentixather may be 
applicable in highly proliferative G3 NET, e.g. after 
failure of 1st or 2nd-line treatments [12]. However, this 
“proof-of-concept“ study definitively needs further 
research enrolling a larger patient cohort, in particular 
as other therapies may alter CXCR4 expression on the 
cell surface [57]. Figure 2 displays a triple-tracer 
approach using [18F]-FDG PET, [68Ga]-DOTATOC and 
[68Ga]-Pentixafor in a G3 NET patient with a Ki67 > 
90%. Tumor heterogeneity in a liver lesion (no 
SSTR-expression, but increased glycolytic activity and 
upregulation of CXCR4) can be appreciated.  
Harmonization of SSTR-Targeted 
PET/CT Interpretation for Standardized 
Treatment  
MI-RADS [7]. While reading SSTR-targeted 
PET/CT scans, certain pitfalls have to be considered 
and false-positive or false-negative findings may also 
have an impact on patient selection for subsequent 
PRRT [58]. Thus, similar to the existing reporting and 
data systems for multiple other organs (BI-RADS for 
breast, or TI-RADS for thyroid), a standardized 
framework system for molecular imaging, titled 
“Molecular Imaging RADS” (MI-RADS), has recently 
been introduced [7, 59, 60]. MI-RADS may serve as an 





attractive option for the interpretation of PET/CTs 
using radiotracers with potential theranostic 
implications and includes PSMA-RADS for 
PSMA-targeted PET/CT (for patients with prostate 
cancer) as well as SSTR-RADS for SSTR-targeted 
PET/CT [8, 61-63]. MI-RADS takes the site of disease 
and the uptake intensity into account, assists the 
reader in navigating through pitfalls and 
indeterminate lesions, facilitates communication with 
referring clinicians, and provides recommendations 
for appropriate workup of equivocal findings. 
Notably, MI-RADS systems (PSMA- and SSTR-RADS) 
can be applied reciprocally, i.e. if the interpreter is 
familiar with the structure of SSTR-RADS for NET, 
PSMA-RADS for prostate cancer can be readily 
applied as well [7]. 
SSTR-RADS [8]. Numerous pitfalls on SSTR- 
targeted PET may complicate the reliable 
interpretation of an SSTR-targeted PET/CT scan [7, 
58]. Apart from physiological biodistribution in 
pituitary glands, major salivary glands, thyroid gland, 
adrenal glands, liver, and spleen, as well as excretion 
via the urinary tract, variable uptake can also be 
appreciated in the uncinate process of the pancreas 
[22, 58]. Other common pitfalls on SSTR-targeted PET 
include inflammatory disease (e.g., sarcoidosis or 
tuberculosis) and non-GEP NET tumors, e.g. breast 
cancer or papillary thyroid carcinoma [58]. Thus, 
SSTR-RADS may increase the reader’s level of 
confidence in interpreting SSTR-PET/CT scans as 
specific categories and recommendations regarding 
those pitfalls are incorporated into the system. In 
brief, SSTR-RADS assigns lesions to a 5-point scale 
(from 1 = definitively benign to 5 = NET certainly 
present) by considering the site of disease and the 
level of uptake defined as a three-point qualitative 
assessment scoring using the relative lesion uptake 
compared to blood pool (Level (L) 1: ≤ blood pool) 
and physiological liver uptake (L 2: uptake > blood 
pool but ≤ liver and L 3: uptake > liver). Each 
SSTR-RADS classification provides instructions for 
the next step in the diagnostic and treatment 
algorithm (a workflow chart for the different 
SSTR-RADS classifications is provided in Figure 3).  
 
Figure 2. Tumor heterogeneity in a patient with a G3 gastric NET and liver metastases in a 67 year old patient suffering from gastric NET with liver metastases 
(Ki67 = 90%, G3 NET). In accordance with G3 NET, hypermetabolic hepatic metastases demonstrate loss of SSTR and up-regulation of CXCR4 expression (solid 
arrows). Moreover, [68Ga]-Pentixafor provides additional information on disease extent by exclusively detecting a coeliac lymph node suspicious for metastatic 
disease (dotted arrows). From Werner et al., Theranostics, [12]. 
 





Table 1. summarizes the reviewed novel theranostic agents, along with respective advantages and limitations. 
Radiotracer  Targeting Advantages Limitations 
[68Ga]-OPS202/ 
[177Lu]-OPS201* 
SSTR Antagonist Prospective phase 1 study: evaluated the safety, biodistribution, dosimetry and optimal 
imaging time point [15] 
Phase 2 study: higher detection rate compared to the SSTR agonist [68Ga]-DOTATOC [17] 
High reproducibility between succeeding [68Ga]-OPS202 scans [17] 
[177Lu]-OPS201 in pigs demonstrated biodistribution acceptable for human application [48] 
Under investigation in an ongoing, recruiting trial (ClinicalTrials.gov Identifier: 
NCT02592707) [50], first published data in 19 patients demonstrated high safety profile 
(maximum of two treatment cycles using [177Lu]-OPS201) [49] 
Further investigations 
enrolling larger patient 






Due to serum albumin binding, markedly extended half-life in the blood and thus, higher 
tumor doses 
Increase in tumor retention in cell lines and SSTR bearing tumor mice using the theranostic 
twins [86Y]/[90Y]-DOTA-EB-TATE [13] 
In humans: 7.9 fold increase in tumor dose delivery using [177Lu]-DOTA-EB-TATE [51] 
Head-to-head comparison with [177Lu]-DOTATATE: the EB-TATE group received 
approximately 1/6 of total radiation exposure compared to the TATE group 
Further investigations are 
warranted (e.g. to determine 








Inverse expression (upregulation of CXCR4 and downregulation of SSTR) with increased 
grading proven by histopathology [56] 
“Proof-of-concept“ study with increased uptake of [68Ga]-Pentixafor in G3 NET (vs. 
markedly decreased/even absent SSTR expression) [12] 
 
To date, no prospective 
investigation using 
[68Ga]-Pentixafor in NET 
Data about treatment in 
NET using 






Successful animal studies using the alpha emitters [213Bi]- and [225AC]-DOTATOC [52, 53] 
TAT in 7 human subjects with [213Bi]-DOTATOC demonstrated long-lasting anti-tumor 
effects, overcame resistance against beta radiation and acceptable adverse side effects [54] 
Further investigations are 





Figure 3. Flow-chart for potential further workup and treatment based on somatostatin receptor reporting and data system (SSTR-RADS) classification [8]. MRI = 
magnetic resonance imaging. 
 
SSTR-RADS-1A refers to benign lesions, without 
any abnormal uptake (L 1) and SSTR-RADS-1B (L 2-3) 
to benign lesions, but with focal uptake (e.g. benign 
prostatic hyperplasia). SSTR-RADS-2 (L 1) includes 
uptake in soft-tissue sites or bone lesions atypical of 
metastatic NET rendering such lesions likely benign, 
e.g. uptake in a bone lesions suggestive to be 
degenerative (e.g. a Schmorl node). SSTR-RADS-3 is 
segregated into 4 sub-classifications and is focused on 
the concept of equivocal findings on SSTR-targeted 
PET, which may need further work-up. 
SSTR-RADS-3A and SSTR-RADS-3B lesions (L 1-2, 
respectively) are suggestive of, but not definitive for 
NET. While SSTR-RADS-3A describes lesions that 
demonstrate equivocal uptake in soft-tissue sites typical 
for NET (e.g. a regional lymph node), SSTR-RADS-3B 
includes such lesions in the skeleton (e.g. low-level 
uptake in the rib). On the other hand, SSTR-RADS-3C 
lesions are suggestive of an SSTR-expressing, non-NET 
benign tumor or malignant process, i.e. uptake (up to L 3) 





at a site highly atypical for NET, such as the breast. 
SSTR-RADS-3D sites are not SSTR-avid and have a 
high likelihood for a dedifferentiated NET lesion or 
another type of non-SSTR-expressing malignancy, i.e. 
further work-up to rule out potential tumor escape or 
secondary malignancy is mandatory. SSTR-RADS-4 
and -5 have both a high level of uptake (L3) at typical 
disease sites. SSTR-RADS-4 does not show 
corresponding findings on conventional imaging, 
while SSTR-RADS-5 does demonstrate such findings. 
Notably, in terms of multiple lesions, an overall scan 
impression can be indicated by establishing an overall 
SSTR-RADS score (highest target lesion score takes 
priority over the other lesion, Figure 4).  
The NETPET Grade [9]. While SSTR-RADS may 
serve as a reliable tool that addresses the need for 
baseline criteria in the field of SSTR-PET, Chan and 
coworkers developed a grading score that unifies a 
dual-tracer assessment with SSTR-targeted agents and 
[18F]-FDG in a single parameter for outcome 
prediction. The NETPET grading scheme has six 
categories and classifies SSTR(-)/FDG(-) patients as 
P0, while patients with exclusively SSTR(+) tumors 
are P1 and patients with exclusively FDG(+) tumors 
are P5. The intermediate groups P2-P4 are both 
SSTR(+) and FDG(+) with variations in the degree of 
relative radiotracer uptake (P2 tumors have FDG < 
SSTR uptake, P3 have FDG = SSTR uptake, and P4 
have FDG > SSTR uptake). Notably, the P2 to P4 
categories can be further divided into “a” and “b”, 
which primarily refers to the number of investigated 
lesions.  
While further validation studies for SSTR-RADS 
(e.g. interobserver studies or comparison of 
SSTR-RADS scoring with histopathological evidence) 
are still lacking, the NETPET Grading Score has been 
retrospectively evaluated and a considerable 
distinction in the survival probability between the P1 
vs. P2-4 vs. P5 groups was recorded (P5, worst 
outcome, P1, best outcome, with P2-4, intermediate 
outcome). Notably, none of the other investigated 
variables (age, extrahepatic disease, histological 
grade) served as an independent outcome predictor, 
while the NETPET grade remained significant in a 
multivariate analysis. Thus, this proposed grading 
scheme may serve as a prognostic biomarker in 
identifying high-risk patients and guide appropriate 
therapy [9]. It may also trigger further workup (e.g. for 
P2a with biopsy of a single FDG(+) lesion) or to 
refrain from PRRT (e.g. for P5 with the vast majority of 
the findings being exclusively FDG(+)). Nonetheless, 
a dual-tracer approach is not routinely applied [64, 
65]. The NETPET Grading Score may be most 
valuable to determine the most effective next steps in 
patients with an intermediate Ki67 and the risk for 




Figure 4. Application of somatostatin receptor reporting and data system (SSTR-RADS) for the interpretation of SSTR-targeted PET/CT [8]. 76 year-old male with 
history of a cancer of unknown primary (most likely primary hepatic NET), which underwent [68Ga]-DOTATOC PET/CT for staging. (A) Whole body maximum 
intensity projection demonstrated multiple suspicious uptake sites (arrowheads). On (B) axial CT, (CT) axial PET and (D) axial PET/CT, mild radiotracer uptake is 
seen in a left supraclavicular lymph node (thin arrow). This lesion was classified as SSTR-RADS 3A by an experienced reader. On (F) axial PET and (G) axial PET/CT, 
intense radiotracer uptake is visualized in the head of the 7th right rib (double thin arrows). As this site of radiotracer uptake did not show corresponding findings on 
(E) axial CT, this finding was classified as SSTR-RADS-4. On (H) axial CT, (I) axial PET and (J) axial PET/CT, intense radiotracer uptake is visualized in a liver lesion 
(segment VII/VIII, arrow), which shows central necrosis and subtle hypodensity on (H) axial CT. Thus, this lesion was classified as SSTR-RADS Score 5. Another liver 
lesion in segment VIII/IVa (arrowhead) also demonstrated intense radiotracer uptake on (I) axial PET and (J) axial PET/CT, but without corresponding findings on (H) 
axial CT, i.e. SSTR-RADS-4. The Overall SSTR-RADS Score was 5. Based on this scoring, peptide receptor radionuclide therapy may be considered [8]. 





Tables 2. (SSTR-RADS) and 3 (NETPET Grading) summarize those standardization systems for the interpretation of SSTR-targeted 
PET/CT scans.  





of RADS Classification 
Uptake 
Level 
Workup?  PRRT? 
1  
definitively benign 
1A benign lesion, characterized by biopsy or anatomic imaging without 
abnormal uptake 
1 n/a N 
1B benign lesion, characterized by biopsy or anatomic imaging with 
abnormal uptake  
 
2-3 n/a N 
2 likely benign  soft-tissue site or bone lesion atypical for metastatic NET (e.g. axillary 
lymph nodes or suspected to be degenerative in nature) 
 
1 n/a N 
3  
suggestive of, but not 
definitive for NET 
3A Equivocal uptake in soft tissue lesion typical for NET metastases (e.g. 
regional lymph node in the midabdomen) 
1-2  B, F/U N 
3B Equivocal uptake in bone lesion not atypical of NET (e.g. low-level 
uptake in a rib) 
1-2  B, F/U N§ 
non-NET malignancy or 





Intense uptake in site highly atypical of all but advanced stages of 
NET (e.g. in the breast) 
3  B N 
high likelihood for 
malignant (NET) lesion, but 
negative/with rather low 




Lesion suggestive of malignancy on anatomic imaging but lacking 






4 NET highly likely  Intense uptake in site typical of NET but lacking definitive findings 
on conventional imaging  
3  n/a Y 
5 NET almost certainly 
present 
 Intense uptake in site typical of NET but with definitive findings on 
conventional imaging  
3  n/a Y 
 
 
Table 3. The NETPET Grade [9]. Categories of NETPET grading descriptors. P = PRRT as a potential therapy. NM = not useful as 
a monotherapy. U = PRRT unlikely to be effective. (+) or (-) = avid or non-avid lesion on PET. 
NETPET  
Grade 
 SSTR- and FDG combination Description of target lesion 




P0  SSTR(-) and FDG(-) n/a  P 
P1  SSTR(+) and FDG(-)  n/a  P 
P2 P2a SSTR(+) and FDG(+) FDG < SSTR 1-2 P 
P2b FDG < SSTR ≥ 3 P 
P3 P3a SSTR(+) and FDG(+) FDG = SSTR 1-2 P 
P3b FDG = SSTR ≥ 3 P 
P4 P4a SSTR(+) and FDG(+) 
 
FDG > SSTR 1-2 P 
P4b FDG > SSTR ≥ 3 NM 
P4b FDG(+), SSTR(-) in 1 lesion, with 1 additional lesion FDG > SSTR  NM 
P5 P5 SSTR(+) and FDG(+) FDG(+), SSTR(-) in 1 lesion, with 2 additional lesions FDG > SSTR  U 
P5 FDG(+), SSTR(-) in >2 lesions  U 
P5 SSTR(-) and FDG(+) n/a  U 
 
 
A Glimpse into the Future 
COMPETE Trial. Apart from the currently 
recruiting trial to assess the safety and efficacy of 
[177Lu]-OPS201, the prospective, multi-centric, 
randomised, controlled, Phase III COMPETE trial 
(ClinicalTrials.gov Identifier: NCT03049189) aims to 
evaluate the impact of [177Lu]-DOTATOC (maximum 
of four cycles, standard activity of 7.5 GBq) in 
GEP-NET patients. As active comparator, the mTOR 
inhibitor Everolimus will be administered in an oral 
standard dose of 10mg. PFS and OS will be assessed 
and the COMPETE trial may allow for further insights 
into the efficacy of PRRT compared to another 
common (United States Food Drug 
Administration-approved) treatment option for NET 
[66].  
Closer Monitoring of Side Effects. With the 
introduction of [177Lu], severe renal impairment or 
nephrotoxicity that were more frequently observed 
with [90Y] have become rather uncommon [67]. 
However, the kidneys are known as the dose-limiting 
organ, and impairment in renal function may lead to 
suspension or even early termination of treatment 
[67]. Thus, closer monitoring of renal function may be 
regarded as one of the cornerstones for continuing 
PRRT with radiolabeled agonists over several cycles 
or for administration of novel radiotracers with 
potentially increased kidney doses [5, 13]. However, 
at the time being, established clinical risk factors 





provide only a limited estimate of nephrotoxicity and 
so far unidentified individual susceptibilities to 
radiation may be present [67]. 
For monitoring renal function, both the tubular 
extraction (TER) as well as glomerular filtration rate 
can be assessed. Since the primary target of radiation 
after PRRT is the proximal tubule, some articles have 
recommended using TER in patient follow-up [5, 68]. 
In contrast, TER measured by [99mTc]- 
mercaptoacetyltriglycine turned out not to be a 
reliable prognostic marker for renal impairment in 
another study [68]. On the other hand, glomerular 
injury is usually the first step in radiation-induced 
kidney injury and more sensitive means of GFR 
assessment may be appropriate. As a novel strategy, 
PET-based approaches to monitor kidney function 
have recently been reported. Hofman et al. introduced 
the renal PET/CT probe [68Ga]- 
ethylenediaminetetraacetic acid ([68Ga]-EDTA) for 
monitoring glomerular filtration rate. Relative to 
conventional 2-dimensional planar scintigraphic 
approaches for measuring renal function, renal 
PET/CT allows for rapid 3-dimensional capability, 
improved spatio-temporal resolution and anatomical 
co-registration. Transferred to the field of NET, 
[68Ga]-EDTA has already been used to rule out severe 
renal injury (e.g. by obstruction) prior to PRRT [69]. 
Therefore, [68Ga]-EDTA or the recently introduced 
renal PET agent 2-deoxy-2-18F-fluorosorbitol 
([18F]-FDS), which can be produced by a simple 
one-step reduction from [18F]-FDG, may overcome the 
hurdles of conventional renal scintigraphy [69-71] and 
be useful tools in the management of PRRT patients 
[70]. 
Dosimetric Approaches. Individual tailored 
treatment in PRRT for NET includes dosimetric 
studies and corresponding dose calculations to ensure 
maximal treatment efficacy at disease sites and 
minimal harm to organs at risk [6, 72]. Using a hybrid 
method of SPECT and planar images, Sundlöv et al. 
performed treatment with [177Lu]-DOTATATE up to a 
renal biologically effective dose of 27 Gy in 51 
subjects. Selected patients were also offered further 
treatment of up to 40 Gy. Notably, none of those 
patients demonstrated significant renal impairment 
and the majority (73%) were able to receive > 4 
treatment cycles. Thus, individualizing PRRT based 
on SPECT increases the number of 
[177Lu]-DOTATATE administrations [73]. Striving for 
a personalized treatment assessment, a currently 
recruiting prospective trial aims to expand the 
concept of SPECT-based dosimetry to NET lesions as 
well: PRRT will be tailored to specific needs of the 
patients, i.e. the absorbed radiation dose to sites of 
disease will be maximized, but limited according to 
the respective organs at risk (NCT02754297) [74]. 
However, the short half-life of 
[68Ga]-DOTATATE/-TOC (68 min) does not allow for 
pre-therapeutic dosimetry based on SSTR-targeted 
PET. Given the time-consuming nature of current 
SPECT dosimetry approaches, which result in a high 
burden for patient and personnel [72, 75], the 
positron-emitter terbium-152 ([152Tb]) may overcome 
this hurdle due to its considerably longer half-life of 
17.5h. Regarded as a diagnostic match to therapeutic 
radiolanthanides like [177Lu], [152Tb] may meet the 
need for PET-based dosimetry [18]. Spearheaded by 
Baum et al., 152Tb was collected via a mass separation 
process at the ISOLDE facility, Cern, Switzerland. In a 
pre-clinical study, [152Tb]-labeled DOTANOC was 
investigated in AR42J tumor-bearing mice and 
[177Lu]-DOTANOC SPECT/CT imaging studies were 
able to confirm [152Tb]-based PET findings [76]. These 
encouraging results led to a proof-of-concept PET 
study using [152Tb]-DOTATOC in a patient suffering 
from NEN of the terminal ileum (Ki67 < 5%) [18]. 
Notably, scans were conducted over a time span of 
24h, allowing for the demarcation of very small 
metastases at late time points. Moreover, due to the 
long half-life of [152Tb], existing delivery networks 
could readily be used and distribution by commercial 
vendors could be viable. As a drawback, the 
availability of this radiotracer is currently limited [18].  
Machine Learning for Theranostics. Artificial 
intelligence (AI) is currently on the forefront of 
research in numerous radiological applications and 
recent efforts in the field of theranostics aimed to 
investigate the capability of outcome prediction using 
software tools for intratumoral heterogeneity 
(radiomics) based on SSTR-targeted SPECT or PET 
[77, 78]. However, machine learning and AI for 
theranostics are not limited to therapy response 
prediction, but could also potentially be applied in 
clinical decision making by the creation of 
multidisciplinary large datasets (clinical information 
obtained from gastroenterology, endocrinology, 
surgery, radiology, nuclear medicine, and pathology). 
Other potential areas of interest are automated 
detection and separation of benign vs. malignant 
findings on SSTR-targeted PET, post-processing of 
obtained imaging data, automated dose estimations 
based on post-therapeutic SPECT, or integrity 
analytics of molecular images [79]. Nonetheless, 
current supervised machine learning approaches need 
continuous input and labeling of data from highly 
experienced radiologists (or in the field of 
theranostics, nuclear medicine physicians) and thus, 
novel approaches to address this issue are needed 
[80]. One potential approach is the introduction of 
Deep Convolutional Generative Adversarial 





Networks (DCGANs), which are primarily used to 
augment existing datasets without time-consuming, 
human labeling procedures (synthetic data 
augmentation). In brief, DCGANs use adversarial 
networks, in which one network is creating artificial 
images, while the other network is continuously 
learning to separate artificial from true images [80-82]. 
For instance, DCGANs could be expanded to the field 
of theranostics, e.g. by augmenting an existing dataset 
of (already conventionally labeled) SSTR-targeted 
PET/CT using SSTR-RADS. Hence, further 
time-consuming labeling procedures by human 
experts could be omitted and finally, (SSTR-)RADS 
reporting could be automated by effective data 
augmentation. This applies especially to “rare“ 
lesions, such as SSTR-RADS-3A or SSTR-RADS-3B 
lesions (indeterminate findings with low-level 
uptake), which may not be encountered to the extent 
that machine learning could be effectively trained 
from real images [8]. As part of MI-RADS, DCGANs 
could also expanded to radioligand therapy and 
PSMA-targeted PET/-RADS [7].  
Conclusions 
25 years after its initial introduction for the 
diagnosis and treatment of NET, the theranostic 
principle is as relevant as ever. The NETTER-1 trial 
demonstrated that PRRT (in combination with 
low-dose octreotide LAR) lengthens the 
time-to-progression, the time to health-related QoL 
deterioration, and increases survival probability [25, 
26]. Moreover, efforts in recent years have expanded 
upon common recommendations from current 
guidelines, such as the dogma to perform a maximum 
of 4 treatment cycles with [177Lu]-SSTR agonists. 
Notably, the concept of PRRT has been also applied 
beyond oncology, e.g. for the treatment of 
granulomatous or other inflammatory disorders [10, 
11, 19]. New framework systems, such as SSTR-RADS 
or NETPET Grading may facilitate communication 
with referring clinicians, but also provide workflows 
of appropriate workup for indeterminate findings [8, 
9]. In addition to established radiotracers for 
theranostics in NET (e.g. [68Ga]-/[177Lu]- 
DOTATATE/-TOC), recent developments of novel 
theranostic ligands may outperform those 
“state-of-the-art” SSTR-targeting agents. Future 
perspectives in the field may focus on supervised 
machine learning for outcome prediction by creating 
large multidisciplinary datasets from different 
disciplines involved in NET management [79, 80]. In 
this light, the theranostics concept has a promising 
future in NET and will continue to play a pivotal role 
in patient care. 
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